Australia's most trusted
source of pharma news
Saturday, 02 August 2025
Posted 31 July 2025 AM
AstraZeneca is seeking expansions to three of its cancer drugs at the November PBAC meeting, seeking new populations for its blockbusters.
AstraZeneca is seeking its first recommendation for immunotherapy Imfinzi to treat bladder cancer, asking for subsidisation for perioperative treatment of patients with muscle invasive bladder cancer who are planning to undergo radical cystectomy and are eligible for cisplatin-based neoadjuvant chemotherapy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.